Literature DB >> 17242401

5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction.

Xiao-Xin Sun1, Mu-Shui Dai, Hua Lu.   

Abstract

5-fluorouracil (5-FU) is a widely used chemotherapeutic drug for the treatment of a variety of solid tumors. The anti-tumor activity of 5-FU has been attributed in part to its ability to induce p53-dependent cell growth arrest and apoptosis. However, the molecular mechanisms underlying p53 activation by 5-FU remain largely obscure. Here we report that 5-FU treatment leads to p53 stabilization and activation by blocking MDM2 feedback inhibition through ribosomal proteins. 5-FU treatment increased the fraction of ribosome-free L5, L11, and L23 ribosomal proteins and their interaction with MDM2, leading to p53 activation and G1/S arrest. Conversely, individual knockdown of these ribosomal proteins by small interfering RNA prevented the 5-FU-induced p53 activation and reversed the 5-FU-induced G1/S arrest. These results demonstrate that 5-FU treatment triggers a ribosomal stress response so that ribosomal proteins L5, L11, and L23 are released from ribosome to activate p53 by ablating the MDM2-p53 feedback circuit.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17242401     DOI: 10.1074/jbc.M610621200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  96 in total

1.  Perturbation of 60 S ribosomal biogenesis results in ribosomal protein L5- and L11-dependent p53 activation.

Authors:  Xiao-Xin Sun; Yue-Gang Wang; Dimitris P Xirodimas; Mu-Shui Dai
Journal:  J Biol Chem       Date:  2010-06-16       Impact factor: 5.157

2.  Identification of ribosomal protein S25 (RPS25)-MDM2-p53 regulatory feedback loop.

Authors:  X Zhang; W Wang; H Wang; M-H Wang; W Xu; R Zhang
Journal:  Oncogene       Date:  2012-07-09       Impact factor: 9.867

3.  Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model.

Authors:  Lili Bao; Aliyya Haque; Kamilah Jackson; Sidhartha Hazari; Krzysztof Moroz; Rachna Jetly; Srikanta Dash
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

4.  Growth inhibitory effects of large subunit ribosomal proteins in melanoma.

Authors:  Gregory R Kardos; Mu-Shui Dai; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2014-06-16       Impact factor: 4.693

5.  Balanced production of ribosome components is required for proper G1/S transition in Saccharomyces cerevisiae.

Authors:  Fernando Gómez-Herreros; Olga Rodríguez-Galán; Macarena Morillo-Huesca; Douglas Maya; María Arista-Romero; Jesús de la Cruz; Sebastián Chávez; Mari Cruz Muñoz-Centeno
Journal:  J Biol Chem       Date:  2013-09-16       Impact factor: 5.157

6.  SUV39H1 regulates human colon carcinoma apoptosis and cell cycle to promote tumor growth.

Authors:  Chunwan Lu; John D Klement; Dafeng Yang; Thomas Albers; Iryna O Lebedyeva; Jennifer L Waller; Kebin Liu
Journal:  Cancer Lett       Date:  2020-02-12       Impact factor: 8.679

7.  mTOR inhibitors blunt the p53 response to nucleolar stress by regulating RPL11 and MDM2 levels.

Authors:  Kaveh M Goudarzi; Monica Nistér; Mikael S Lindström
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

8.  Doxorubicin and 5-fluorouracil induced accumulation and transcriptional activity of p53 are independent of the phosphorylation at serine 15 in MCF-7 breast cancer cells.

Authors:  Matthew T Balmer; Ryan D Katz; Si Liao; James S Goodwine; Susannah Gal
Journal:  Cancer Biol Ther       Date:  2014-05-06       Impact factor: 4.742

9.  Synergistic anticancer effect of exogenous wild-type p53 gene combined with 5-FU in human colon cancer resistant to 5-FU in vivo.

Authors:  Qi Xie; Min-Yi Wu; Ding-Xuan Zhang; Yi-Ming Yang; Bao-Shuai Wang; Jing Zhang; Jin Xu; Wei-De Zhong; Jia-Ni Hu
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

10.  Defects in 18 S or 28 S rRNA processing activate the p53 pathway.

Authors:  Michael Hölzel; Mathias Orban; Julia Hochstatter; Michaela Rohrmoser; Thomas Harasim; Anastassia Malamoussi; Elisabeth Kremmer; Gernot Längst; Dirk Eick
Journal:  J Biol Chem       Date:  2010-01-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.